A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection

Journal of Virology

Volumn 85, Issue 5, 2011, Pages 2397-2405

  Musich, Thomas ^a   Peters, Paul J ^a   Duenas Decamp, Maria José ^a   Gonzalez Perez, Maria Paz ^a   Robinson, James ^b   Zolla Pazner, Susan ^c   Ball, Jonathan K ^d   Luzuriaga, Katherine ^a   Clapham, Paul R ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; SOLUBLE CD4 ANTIGEN;

AIDS PATIENT; AMINO ACID ANALYSIS; AMINO ACID SUBSTITUTION; ANTIBODY COMBINING SITE; ARTICLE; AUTOPSY; CD4+ T LYMPHOCYTE; CELL SURFACE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; EXPOSURE; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; VIRION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; ANTIGENS, CD4; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CONSERVED SEQUENCE; HELA CELLS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MACROPHAGES; MOLECULAR SEQUENCE DATA; SEQUENCE ALIGNMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79551700244     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02187-10     Document Type: Article

References (51)

1. Baeten, J. M., et al. 2007. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J. Infect. Dis. 195:1177-1180.
2. Bannert, N., D. Schenten, S. Craig, and J. Sodroski. 2000. The level of CD4 expression limits infection of primary rhesus monkey macrophages by a T-tropic simian immunodeficiency virus and macrophage-tropic human immunodeficiency viruses. J. Virol. 74:10984-10993. (Pubitemid 32223963)
3. Binley, J. M., et al. 2004. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78:13232-13252. (Pubitemid 39507829)
4. Blish, C. A., M. A. Nguyen, and J. Overbaugh. 2008. Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. PLoS Med. 5:e9.
5. Carrington, M., M. Dean, M. P. Martin, and S. J. O'Brien. 1999. Genetics of HIV-1 infection: chemokine receptor CCR5 polymorphism and its consequences. Hum. Mol. Genet. 8:1939-1945.
6. Cavarelli, M., and G. Scarlatti. 2009. Phenotype variation in human immunodeficiency virus type 1 transmission and disease progression. Dis. Markers 27:121-136.
7. Chen, B., et al. 2005. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433:834-841. (Pubitemid 40314887)
8. Chen, L., et al. 2009. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326:1123-1127.
9. Clapham, P. R., and A. McKnight. 2002. Cell surface receptors, virus entry and tropism of primate lentiviruses. J. Gen. Virol. 83:1809-1829.
10. Duenas-Decamp, M. J., P. Peters, D. Burton, and P. R. Clapham. 2008. Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop. J. Virol. 82:5807-5814.
11. Duenas-Decamp, M. J., P. J. Peters, D. Burton, and P. R. Clapham. 2009. Determinants flanking the CD4 binding loop modulate macrophage tropism of human immunodeficiency virus type 1 R5 envelopes. J. Virol. 83:2575-2583.
12. Duenas-Decamp, M. J., et al. 2010. Variation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis. Future Virol. 5:417-433.
13. Dunfee, R. L., et al. 2006. The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc. Natl. Acad. Sci. U. S. A. 103:15160-15165.
14. Easterbrook, P. J., et al. 2010. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J. Int. AIDS Soc. 13:4.
15. Esbjornsson, J., et al. 2010. Frequent CXCR4 tropism of HIV-1 subtype A and CRF02-AG during late-stage disease: indication of an evolving epidemic in West Africa. Retrovirology 7:23.
16. Gorry, P. R., et al. 2001. Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J. Virol. 75:10073-10089. (Pubitemid 32948038)
17. Gorry, P. R., et al. 2002. Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J. Virol. 76:6277-6292. (Pubitemid 34556323)
18. Gray, L., et al. 2005. Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome. Virology 337:384-398. (Pubitemid 40799005)
19. Kaleebu, P., et al. 2002. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J. Infect. Dis. 185:1244-1250.
20. + T-cell decline among HIV seroincident antiretroviral naive persons in Rakai district, Uganda. J. Acquir. Immune Defic. Syndr. 54:180-184.
21. Koyanagi, Y., et al. 1987. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 236:819-822. (Pubitemid 17071156)
22. Kulkarni, S. S., et al. 2009. Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. Virology 385:505-520.
23. Kwong, P. D., et al. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659. (Pubitemid 28289647)
24. Lee, B., M. Sharron, L. J. Montaner, D. Weissman, and R. W. Doms. 1999. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc. Natl. Acad. Sci. U. S. A. 96:5215-5220.
25. Li, S., et al. 1999. Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates. J. Virol. 73:9741-9755.
26. Li, Y., et al. 2008. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J. Virol. 82:638-651.
27. Liu, J., A. Bartesaghi, M. J. Borgnia, G. Sapiro, and S. Subramaniam. 2008. Molecular architecture of native HIV-1 gp120 trimers. Nature 455:109-113.
28. Ly, A., and L. Stamatatos. 2000. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. J. Virol. 74:6769-6776. (Pubitemid 30470659)
29. Lynch, R. M., et al. 2010. Subtype-specific conservation of isoleucine 309 in the envelope V3 domain is linked to immune evasion in subtype C HIV-1 infection. Virology 404:59-70.
30. Martin, J., C. C. LaBranche, and F. Gonzalez-Scarano. 2001. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate. J. Virol. 75:3568-3580. (Pubitemid 32246366)
31. Martin-Garcia, J., W. Cao, A. Varela-Rohena, M. L. Plassmeyer, and F. Gonzalez-Scarano. 2006. HIV-1 tropism for the central nervous system: brain-derived envelope glycoproteins with lower CD4 dependence and reduced sensitivity to a fusion inhibitor. Virology 346:169-179. (Pubitemid 43254708)
32. Montefiori, D. C., and J. R. Mascola. 2009. Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? Curr. Opin. HIV AIDS 4:347-351.
33. Mori, K., M. Rosenzweig, and R. C. Desrosiers. 2000. Mechanisms for adaptation of simian immunodeficiency virus to replication in alveolar macrophages. J. Virol. 74:10852-10859.
34. O'Doherty, U., W. J. Swiggard, and M. H. Malim. 2000. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J. Virol. 74:10074-10080.
35. O'Rourke, S. M., et al. 2010. Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus. J. Virol. 84:11200-11209.
36. Peters, P. J., et al. 2004. Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusogenicity for macrophages. J. Virol. 78:6915-6926. (Pubitemid 38781530)
37. Peters, P. J., et al. 2008. Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors. Retrovirology 5:5.
38. Peters, P. J., et al. 2006. Non-macrophage-tropic human immunodeficiency virus type 1 R5 envelopes predominate in blood, lymph nodes, and semen: implications for transmission and pathogenesis. J. Virol. 80:6324-6332. (Pubitemid 43927435)
39. Pinter, A., et al. 2004. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J. Virol. 78:5205-5215. (Pubitemid 38581472)
40. Sacktor, N., et al. 2009. HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin. Infect. Dis. 49:780-786.
41. Shieh, J. T., J. Martin, G. Baltuch, M. H. Malim, and F. Gonzalez-Scarano. 2000. Determinants of syncytium formation in microglia by human immunodeficiency virus type 1: role of the V1/V2 domains. J. Virol. 74:693-701. (Pubitemid 30036205)
42. Simmons, G., et al. 1996. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dualtropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J. Virol. 70:8355-8360. (Pubitemid 26378410)
43. Thomas, E. R., et al. 2007. Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. Virology 360:105-119.
44. Tuttle, D. L., et al. 2002. Increased replication of non-syncytium- inducing HIV type 1 isolates in monocyte-derived macrophages is linked to advanced disease in infected children. AIDS Res. Hum. Retrovir. 18:353-362.
45. Vasan, A., et al. 2006. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin. Infect. Dis. 42:843-852.
46. Walker, L. M., et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
47. Wei, X., et al. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
48. Wyatt, R., et al. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705-711. (Pubitemid 28289663)
49. Ye, Y., Z. H. Si, J. P. Moore, and J. Sodroski. 2000. Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo. J. Virol. 74:11955-11962. (Pubitemid 32222346)
50. Zhu, C. B., L. Zhu, S. Holz-Smith, T. J. Matthews, and C. H. Chen. 2001. The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012. Proc. Natl. Acad. Sci. U. S. A. 98:15227-15232.
51. Zolla-Pazner, S., and T. Cardozo. 2010. Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat. Rev. Immunol. 10:527-535.